Efficacy and Safety of GDC-0853 in Participants With Refractory Chronic Spontaneous Urticaria (CSU)



Status:Recruiting
Conditions:Skin and Soft Tissue Infections, Dermatology
Therapuetic Areas:Dermatology / Plastic Surgery
Healthy:No
Age Range:18 - 75
Updated:12/1/2018
Start Date:May 26, 2017
End Date:January 23, 2019
Contact:Reference study Id Number: GS39684 www.roche.com/about_roche/roche_worldwide.htm
Email:global-roche-genentech-trials@roche.com
Phone:888-662-6728 (U.S. Only)

Use our guide to learn which trials are right for you!

A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Pilot and Dose-Ranging Study of GDC-0853 in Patients With Refractory Chronic Spontaneous Urticaria (CSU)

The purpose this study is to evaluate the efficacy, safety, and pharmacokinetics of GDC-0853
compared with placebo in participants with Chronic Spontaneous Urticaria (CSU) refractory to
anti-histamines.


Inclusion Criteria:

- Aged 18−75 years, inclusive

- Diagnosis of chronic spontaneous urticaria (CSU) refractory to H1 antihistamines at
the time of randomization

- Willing and able to complete an Urticaria Participant Daily eDiary for the duration of
the study

- No evidence of active or latent or inadequately treated infection with tuberculosis
(TB)

- Partcipants with a history of Bacille Calmette-Guérin (BCG) vaccination should be
screened using the QuantiFERON-TB-Gold (QFT) test

- Only for participants currently receiving proton-pump inhibitors (PPIs) or H2 receptor
antagonists (H2RAs): Treatment must be at a stable dose during the 2-week screening
period prior to randomization and with a plan to remain at a stable dose for the
duration of the study

- For women of childbearing potential: Agreement to remain abstinent (refrain from
heterosexual intercourse) or use contraceptive methods that result in a failure rate
of <1% per year during the treatment period and for at least 4 weeks after the last
dose of study drug. Women must refrain from donating eggs during this same period.

Exclusion Criteria:

- Treatment with omalizumab or other monoclonal antibody therapies used to treat CSU
within 4 months prior to screening or primary nonresponse to omalizumab

- Use of a non-biologic investigational drug or participation in an investigational
study with a non-biologic drug within 30 days prior to study drug administration on
Day 1 (or within 5 half-lives of the investigational product, whichever is greater)

- Use of a biologic investigational therapy or participation in an investigational study
involving biologic therapy within 90 days or 5 half-lives, whichever is greater, prior
to study drug administration on Day 1

- Previous treatment with GDC-0853 or other Bruton's tyrosine kinase (BTK) inhibitors

- Participants whose urticaria is solely due to physical urticaria

- Other diseases with symptoms of urticaria or angioedema, including urticarial
vasculitis, urticaria pigmentosa, erythema multiforme, mastocytosis, hereditary or
acquired angioedema, lymphoma, or leukemia

- Atopic dermatitis, bullous pemphigoid, dermatitis herpetiformis, or other skin disease
associated with itch such as psoriasis

- Routine doses of the following medications within 30 days prior to screening: systemic
or cutaneous (topical) corticosteroids (prescription or over the counter),
hydroxychloroquine, methotrexate, cyclosporine, or cyclophosphamide

- Prior utilization of intravenous (IV) steroids for treatment of laryngeal angioedema

- Intravenous immunoglobulin G (IV IG) or plasmapheresis within 30 days prior to
screening

- History of anaphylactic shock without clearly identifiable avoidable antigen

- Hypersensitivity to GDC-0853 or any component of the formulation

- Major surgery within 8 weeks prior to screening or surgery planned prior to end of
study (12 weeks after randomization)

- Require any prohibited concomitant medications

- History of live attenuated vaccine within 6 weeks prior to randomization or
requirement to receive these vaccinations at any time during study drug treatment

- Evidence of clinically significant cardiac, neurologic, psychiatric, pulmonary, renal,
hepatic, endocrine, metabolic, or gastrointestinal (GI) disease that, in the
investigator's opinion, would compromise the safety of the participant, interfere with
the interpretation of the study results or otherwise preclude participant
participation

- Current treatment with astemizole, terfenadine, and/or ebastine

- Uncontrolled disease states, such as asthma, psoriasis, or inflammatory bowel disease,
where flares are commonly treated with oral or parenteral corticosteroids
We found this trial at
17
sites
4202 E Fowler Ave
Tampa, Florida 33620
(813) 974-2011
University of South Florida The University of South Florida is a high-impact, global research university...
?
mi
from
Tampa, FL
Click here to add this to my saved trials
104 SE 1st Avenue
Ocala, Florida 34471
352-629-5800
?
mi
from
Ocala, FL
Click here to add this to my saved trials
2121 17th Street
Bakersfield, California 93301
?
mi
from
Bakersfield, CA
Click here to add this to my saved trials
Birmingham, Alabama 35209
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
Boerne, Texas 78006
?
mi
from
Boerne, TX
Click here to add this to my saved trials
?
mi
from
Burlington, VT
Click here to add this to my saved trials
?
mi
from
East Providence, RI
Click here to add this to my saved trials
Gilbert, Arizona 85234
?
mi
from
Gilbert, AZ
Click here to add this to my saved trials
Mission Viejo, California 92691
?
mi
from
Mission Viejo, CA
Click here to add this to my saved trials
Redwood City, California 94063
?
mi
from
Redwood City, CA
Click here to add this to my saved trials
Richmond, Virginia
?
mi
from
Richmond, VA
Click here to add this to my saved trials
Riverside, California 92506
?
mi
from
Riverside, CA
Click here to add this to my saved trials
Scottsdale, Arizona 85251
?
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Seattle, Washington 98115
?
mi
from
Seattle, WA
Click here to add this to my saved trials
?
mi
from
Tulsa, OK
Click here to add this to my saved trials
Upland, California 91786
?
mi
from
Upland, CA
Click here to add this to my saved trials
Vancouver, British Columbia V6T 1W5
?
mi
from
Vancouver,
Click here to add this to my saved trials